0H7R Stock Overview
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Abeona Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.01 |
| 52 Week High | US$8.80 |
| 52 Week Low | US$3.12 |
| Beta | 1.45 |
| 1 Month Change | 1.07% |
| 3 Month Change | -8.67% |
| 1 Year Change | 4.11% |
| 3 Year Change | -22.52% |
| 5 Year Change | n/a |
| Change since IPO | -98.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0H7R | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 6.3% | 3.3% | 1.3% |
| 1Y | 4.1% | -23.4% | 4.3% |
Return vs Industry: 0H7R exceeded the UK Biotechs industry which returned -23.4% over the past year.
Return vs Market: 0H7R matched the UK Market which returned 4.3% over the past year.
Price Volatility
| 0H7R volatility | |
|---|---|
| 0H7R Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0H7R has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0H7R's weekly volatility has decreased from 13% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 84 | Vish Seshadri | www.abeonatherapeutics.com |
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy.
Abeona Therapeutics Inc. Fundamentals Summary
| 0H7R fundamental statistics | |
|---|---|
| Market cap | US$256.91m |
| Earnings (TTM) | -US$71.03m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.6x
P/E RatioIs 0H7R overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0H7R income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$31.40m |
| Gross Profit | -US$31.40m |
| Other Expenses | US$39.63m |
| Earnings | -US$71.03m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.63 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 40.7% |
How did 0H7R perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 01:04 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Abeona Therapeutics Inc. is covered by 22 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| George Zavoico | B. Riley Securities, Inc. |
| Elemer Piros | Cantor Fitzgerald & Co. |